Immunobiomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals

Purpose: We investigated the presence of autoantibodies as immunobiomarkers to a panel of tumor-associated antigens in a group of individuals with small cell lung cancer (SCLC), a disease group that has a poor overall cancer prognosis and therefore may benefit most from early diagnosis. Experimental Design: Sera from 243 patients with confirmed SCLC and normal controls matched for age, sex, and smoking history were analyzed for the presence of these early immunobiomarkers (i.e., autoantibodies to p53, CAGE, NY-ESO-1, GBU4-5, Annexin I, SOX2, and Hu-D) by ELISA. Results: Autoantibodies were seen to at least 1 of 6 antigens in 55% of all the SCLC patients' sera tested, with a specificity of 90% compared with controls. Using a higher assay cutoff to achieve a specificity of 99%, autoantibodies were still detectable in 42% of SCLC patients (receiver operator characteristic area under the curve = 0.76). There was no significant difference in sensitivity when analyzed by stage of the cancer or by patient age or gender. The frequency of autoantibodies to individual antigens varied, ranging from 4% for GBU4-5 to 35% for SOX2. Levels of Annexin I autoantibodies were not elevated in patients with SCLC. Antibodies were also detected in 4 separate patients whose sera were taken up to 3 months before tumor diagnosis. Conclusion: The presence of an autoantibody to one or more cancer-associated antigens may provide an important addition to the armamentarium available to the clinician to aid early detection of SCLC in high-risk individuals. Clin Cancer Res; 17(6); 1474–80. ©2011 AACR.

[1]  J. Robertson,et al.  Autoantibodies in breast cancer: their use as an aid to early diagnosis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Duffy,et al.  Lung cancer screening: the way forward , 2008, British Journal of Cancer.

[3]  A. Nicholson,et al.  The Role of Surgery in the Treatment of Limited Disease Small Cell Lung Cancer: Time to Reevaluate , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Ugur Sahin,et al.  Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. , 2006, Cancer letters.

[5]  J. Robertson,et al.  Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. , 2010, Lung cancer.

[6]  A. Twijnstra,et al.  SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A Murray,et al.  Autoantibodies in lung cancer: possibilities for early detection and subsequent cure , 2007, Thorax.

[8]  B. Lang,et al.  Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer , 2008, Journal of Neuroimmunology.

[9]  N. Malats,et al.  Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. D'Orsi,et al.  Diagnostic Performance of Digital Versus Film Mammography for Breast-Cancer Screening , 2005, The New England journal of medicine.

[11]  P. Boyle,et al.  Clinical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Chuchalin,et al.  Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. , 2004, Lung cancer.

[13]  D. Jackman,et al.  Small-cell lung cancer , 2005, The Lancet.

[14]  Jacqueline Palace,et al.  Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome , 1997, Journal of the Neurological Sciences.

[15]  J. Herman,et al.  Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. , 2005, The Journal of thoracic and cardiovascular surgery.

[16]  Edward L Spitznagel,et al.  Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Stromberg,et al.  Profiling Tumor-Associated Antibodies for Early Detection of Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  Mithat Gonen,et al.  Frequency of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients with small cell lung carcinoma and their correlation with clinical parameters , 2005, Cancer.

[19]  B. Stewart,et al.  World Cancer Report , 2003 .

[20]  E. Apostolakis,et al.  Current role of surgery in small cell lung carcinoma , 2009, Journal of cardiothoracic surgery.

[21]  P. Kvale,et al.  Update in screening of lung cancer , 2005, Respirology.

[22]  G. Cooper,et al.  The epidemiology of autoimmune diseases. , 2003, Autoimmunity reviews.

[23]  S. London,et al.  Low level anti-Hu reactivity: A risk marker for small cell lung cancer? , 2009, Cancer detection and prevention.

[24]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[25]  J. Jett,et al.  Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[27]  J. Robertson,et al.  Two-step method to isolate target recombinant protein from co-purified bacterial contaminant SlyD after immobilised metal affinity chromatography. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[28]  S. Hanash,et al.  Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E. Tan.  Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. , 2001, The Journal of clinical investigation.

[30]  Lars Alfredsson,et al.  Smoking as a trigger for inflammatory rheumatic diseases , 2007, Current opinion in rheumatology.

[31]  C. Begg,et al.  Variations in lung cancer risk among smokers. , 2003, Journal of the National Cancer Institute.

[32]  Jian-ying Zhang.  Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. , 2004, Cancer detection and prevention.

[33]  R. Stahel,et al.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC). , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Goudevenos,et al.  High prevalence of anti-cardiolipin and other autoantibodies in a healthy elderly population. , 1987, Clinical and experimental immunology.

[35]  S. Pinder,et al.  Autoantibodies in early breast cancer , 2005 .

[36]  Matthew B Schabath,et al.  A risk model for prediction of lung cancer. , 2007, Journal of the National Cancer Institute.

[37]  Shotai Kobayashi,et al.  Antinuclear antibodies in healthy aging people: a prospective study , 1995, Mechanisms of Ageing and Development.

[38]  C. Caruso,et al.  Prevalence of organ-specific and non organ-specific autoantibodies in healthy centenarians , 1997, Mechanisms of Ageing and Development.

[39]  K. Hemminki,et al.  p53 autoantibodies predict subsequent development of cancer , 2005, International journal of cancer.

[40]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[41]  J. Koziol,et al.  Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[42]  J. Robertson,et al.  Technical validation of an autoantibody test for lung cancer , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.